...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

Sartorius Officially Opens Production Facility for Bioreactors in Guxhagen, Germany

| Print |
Wednesday, 12 September 2012 14:30 (UTC + 2)

sartorius_logo

- 18 million euros invested in the expansion of manufacturing capacity

Goettingen | Guxhagen, Germany, September 12, 2012 / B3C newswire / - Today on Wednesday, Sartorius, the Goettingen-based laboratory and pharmaceutical supplier, formally opened its new plant in Guxhagen in northern Hesse for the manufacture of bioreactors. After approximately one year of construction, the new building was officially dedicated in the presence of the prime minister of the state government of Hesse, Volker Bouffier; the mayor of the community of Guxhagen, Edgar Slawik; as well as numerous guests from the local political and business community.

Approximately 18 million euros were invested in the plant at which Sartorius now manufactures bioreactors and further production equipment for customers in the biopharmaceutical industry. Covering a total area of nearly 10,000 square feet, the new building complex provides space for a high-tech manufacturing hall and offices for around 240 employees. The building owner is Robos GmbH, from which Sartorius has rented the premises in a long-term lease. By opening this new site in Guxhagen, Sartorius has moved from its former bioreactor production facility in Melsungen, Germany, where it had reached maximum capacity limits.

Prime Minister Volker Bouffier stated after a tour of the plant, “By deciding to build a new production facility just a few kilometers away from Melsungen, Sartorius AG has reinforced its close ties with northern Hesse. At the same time, this decision also underscores the advantages of the business location of the State of Hesse, according to him: “We offer companies an excellent infrastructure and intentionally promote the regional economy so that innovative medium-sized companies will invest in and stay with us,” said the Prime Minister. 

“The new plant enables us to substantially enhance our manufacturing processes and creates additional capacity for us in view of the rising demand for biopharmaceutical production equipment. As a result, we are optimally prepared for further expansion, especially for single-use bioreactors,” said Joachim Kreuzburg, the CEO and Executive Board Chairman of Sartorius AG.


Current Image Files

New Sartorius production facility in Guxhagen, Germany:
http://www.sartorius.com/fileadmin/media/global/company/guxhagen_building.jpg

Manufacture of bioreactors:
http://www.sartorius.com/fileadmin/media/global/company/guxhagen_production.jpg

Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius AG:
http://www.sartorius.com/fileadmin/media/global/company/joachim_kreuzburg_1.jpg 

 

This press release contains statements about the future development of the Sartorius Group. The content of these statements cannot be guaranteed as they are based on assumptions and estimates that harbor certain risks and uncertainties.

This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version. Furthermore, Sartorius reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected. 

 
A Profile of Sartorius
The Sartorius Group is a leading international laboratory and process technology provider covering the segments of Bioprocess Solutions, Lab Products & Services and Industrial Weighing. In 2011, the technology group earned sales revenue of 733.1 million euros. Founded in 1870, the Goettingen-based company currently employs more than 5,000 persons. The major areas of activity of its Bioprocess Solutions segment cover filtration, fluid management, fermentation, cell cultivation and purification, and focus on production processes in the biopharmaceutical industry. The Lab Products & Services segment primarily manufactures laboratory instruments and consumables. Industrial Weighing concentrates on weighing, monitoring and control applications in the manufacturing processes of the food, chemical and pharma sectors. Sartorius has its own production facilities in Europe, Asia and America as well as sales subsidiaries and local commercial agencies in more than 110 countries.


Contact

Petra Kirchhoff
Vice President of Group Corporate Communications and of Investor Relations
+49.(0)551.308.1686
This e-mail address is being protected from spambots. You need JavaScript enabled to view it